NCT06095752Completed
Multiple Myeloma Prognostic Indices
Spectrum of Blood Viscosity , Albumin / Fibrinogen Ratio and Red Cell Distribution Width in Newly Diagnosed Multiple Myeloma Patients. Observation Study
Source: ClinicalTrials.gov · Last updated 2 Oct 2025
Brief summary (registry, in English)
The aim of this study was to evaluate the impact of albumin / fibrinogen ratio, blood viscosity and RDW on the prognosis of a newly diagnosed MM patients
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 48 (actual)
- First submitted
- 27 Sept 2023
- Start date
- 1 Apr 2023
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Assiut University
- Diseases
- Multiple myeloma, Childhood cancers
- NCT number
- NCT06095752
What you commit to
- Study type: Observational
- Participants enrolled: 48
- From 1 Apr 2023 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient previously diagnosed MM and started treatment or in post treatment follow up
Who the study is looking for
- Patients newly diagnosed with MM according to International Myeloma Working Group criteria 2016.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assiut University hospital Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.